Persistence through integration: Assessing the Manus-Inscripta merger, through the GTESI lens
This past week, we reported that Manus and Inscripta have announced a strategic merger to establish an end-to-end platform for scalable development, biomanufacturing, and commercialization of bioalternative products. In our report, we noted the public rationale: by combining Inscripta’s whole-genome engineering technologies with Manus’ cell factory engineering platform, biomanufacturing expertise, and commercialization capabilities, the merged […]











